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Abstract
Background: Escherichia coli is part of the normal human intestinal 
microflora, although it has the potential of causing a variety of invasive 
and diarrheal diseases. It is also a frequent cause of community- and 
hospital-acquired urinary tract infections. Intestinal E. coli has the po-
tential to rapidly develop multidrug resistant (MDR) and to emerge as 
extended-spectrum β-lactamases (ESBLs)-producer. 
Methods: Over the period of July through November, 2015; 287 
stool samples were collected from Jordanian adults who visited the 
students’ clinic of the University of Jordan. Fecal samples were co-
llected and cultured for isolation of E. coli. The isolates were in-
vestigated for antimicrobial susceptibility, and molecular method of 
polymerase chain reaction (PCR) was performed for the detection 
genes of ST131 clone, blaCTX-M group I, blaCTX-M-15, blaNDM-1, 
blaVIM, blaIMP, blaOXA-48, blaKPC and fluoroquinolones resistance 
(gyrA and parC). 
Results: A total of 105/287 E. coli isolates (36.6%) were found to be 
MDR to at least 3 classes of antibiotics, of these 45.1% were ESBL-
producers. A total of 51 representative MDR isolates indicated the 
following; 49% were found positive for ST131 clone, 58.8% were 
resistant for ciprofloxacin, and 41.2% were positive for CTX-M group 
I and CTX-M-15, respectively. All these MDR isolates were also positive 
for mutated both gyrA and parC genes, and only 6/51 isolates (11.8%) 
were positive for each blaNDM-1 and blaKPC. One out of 51 MDR 
isolates (2%) was positive for blaVIM, and none of these isolates was 
positive for blaIMP nor blaOXA-48 genes. 
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Introduction
The increased incidence of ESBLs, that make Gram-
negative bacteria frequently resistant to penicillins, 
cephalosporins and aztreonam by hydrolyzing them, 
is becoming a global health problem [1]. 
Class of CTX-M type enzymes are the most pre-
valent extended-spectrum β-lactamases (ESBLs) 
worldwide including Arab Middle East countries [2, 
3]. Among the CTX-M type enzymes, CTX-M-15 
has been frequently found in Arab countries over 
the last decade [3-7]. 
Carbapenems are part of the last line of defen-
se against serious or invasive infections caused by 
extremely drug-resistant Gram-negative pathogens 
producing ESBLs [8-9].
Prior to the last decade, carbapenem resistance 
in Enterobacteriaceae was rare. However, Klebsie-
lla pneumonia carbapenemase (KPC), New Delhi 
metallo-β-lactamase-1 (NDM-1), and recently oxaci-
llinase-48 (OXA-48) have been reported in Entero-
bacteriaceae isolates [10]. 
E. coli species are currently classified into four 
main phylogenetic groups (A, B1, B2, and D), whe-
re A and B1 groups are mainly commensal stra-
ins, whereas extraintestinal pathogenic strains are 
mostly part of B2 and D groups. The clone that 
belong to the B2 phylogenetic subgroup I, cha-
racterized by the multilocus sequence type (MLST) 
131 and exhibits a specific O25 type (O25b) [11]. 
This new discovered ST131 clone has been recently 
isolated from a diverse range of infections cau-
sed in community and hospitalized patients across 
the world, and it has been found as ESBL CTX-
M-15-producer with a high virulence potential. In 
addition, ST131 clone has been reported to cause 
major infection complications from cystitis to life-
threatening sepsis in many countries [4, 12-14]. 
Fluoroquinolones and trimethoprim are no longer 
effective for empiric therapy of E. coli ST131 infec-
tions [13-16]. 
This study investigated the occurrence rate of ES-
BLs, especially metallo-β-lactamases and ST131 clo-
ne among E. coli colonized intestines of Jordanian 
adults.
Population and Methods 
Subjects and data collection
A total of 287 feces samples using wet sterile cotton 
swab immersed in 3 ml 0.85% sterile normal saline 
tube had been collected from students (one sam-
ple from each person) whom age ranged between 
18 to 35 years old visiting the University of Jordan 
Students’ Clinic in the period from July 2015 to No-
vember 2015. Samples were transported within few 
hours to the microbiology research lab for culture 
and further investigation.
Conclusion: This study indicated that a relatively high rates of com-
mensal fecal E. coli isolates from Jordanian adults were MDR, ESBLs-
producer and belonging to ST131 clone. Also, high rates of CTX-M-15 
and fluoroquinolones resistance were found among MDR E. coli iso-
lates. 
Keywords
Fecal E.coli ST131; Antimicrobial Resistance; ESBls; Jordanian Adults. Received 19-09-2017; Accepted 14-10-2017 
The InTernaTIonal arabIc Journal of anTImIcrobIal agenTs 
ISSN: 2174-9094
2017
Vol. 7 No. 2:5
doi: 10.3823/0810
© Under License of Creative Commons Attribution 3.0 License 3
The biographic data for each student was ob-
tained and registered on a prepared sheet which 
included the following: name, gender, age, univer-
sity number, presence of infection and history of 
antibiotic treatment during the last 6 months before 
sampling their stool (Table 2). 
Culture and identification of E. coli 
All collected swabs were cultured directly on Mac-
Conkey agar and incubated for 24 hours in 37°C. 
Five colonies that morphologically represent E. coli-
like growth were selected from MacConkey culture 
plates and sub-cultured on MacConkey again to 
obtain pure E. coli isolates. Lactose–fermenter pure 
growth on sub-culture plates were confirmed to be 
E. coli by standard biochemical tests, including ci-
trate utilization, lactose and glucose fermentation 
on Kligler iron agar tubes, urease and indole pro-
duction. All confirmed cultures of E. coli isolates 
were stored in cryotubes that contain Mueller-Hin-
ton agar with 15% glycerol and were stored at -70 
ºC. E. coli isolates were later used for antimicrobial 
susceptibility test, DNA extraction and polymerase 
chain reaction (PCR) tests.
Antimicrobial susceptibility testing
E. coli isolates were tested using antimicrobial sus-
ceptibility disc diffusion method according to the 
recommendation of the Clinical Laboratory and 
Standards Institute (CLSI) 2015 [17]. The results were 
interpreted according to the breakpoints of tested 
antibiotics as recommended in CLSI 2015 guideli-
nes. E. coli ATCC® 25922 (ATCC® is a registered 
trademark of the American Type Culture Collection) 
was used as control strain. Minimum inhibitory con-
centration (MIC) using E-test were used for testing 
MDR E. coli isolates (Multi-drug resistant; which are 
resistant to at least 3 classes of antibiotics) including 
resistant for ciprofloxacin and carbapenemase. The 
results of susceptibility tests were interpreted accor-
ding to the guidelines of CLSI.
Extraction of DNA 
E. coli isolates stored in cryotubes at -70ºC were 
thawed at room temperature and cultured onto 
MacConkey agar. After incubation at 37ºC for 24 
hours, a few colonies were picked from the agar, 
inoculated into Mueller-Hinton broth and incubated 
at 37ºC for 18 hours (overnight). Then, the bacterial 
DNA was extracted using the Wizard genomic DNA 
Purification Kit, Promega, (USA) following manufac-
tures instructions. DNA extracted for each E. coli 
isolate was quantified to ensure that it is significant 
for PCR (Concentration > 50 ng/μL), with a purity 
at A260/A280=1.6-1.8, using Thermo Scientific Na-
noDrop 1000 Spectrophotometer.
Detection of ESBLs, KPC and ST131 
E. coli isolates in cryotubes stored at -70ºC were 
thawed at room temperature, and cultured onto 
MacConkey agar. After incubation at 37 ºC overnight 
few colonies were picked from the agar, and inocu-
lated into 3ml Luria Broth (LB) and incubated for 24 
hours at 37ºC. The bacterial plasmid was extracted 
using the Zyppy™ Plasmid Miniprep Kit, Zymo (USA) 
according to manufacturer’s instructions. Plasmid 
extraction was done for the identification of plas-
mid encoded β-lactamases genes (blaCTX-M group 
I, blaCTX-M-15, blaKPC, blaNDM-1, blaOXA-48, 
blaIMP and blaVIM). All Primer targets, sequences, 
product size and their references are shown in Ta-
ble 1. The following controls  strains were used: 
K. pneumonia (ATCC BAA-1705), K. pneumoniae 
ATCC BAA-2146; CMUL E. coli CL 502; CMUL P. 
aeruginosa 132, CMUL P. aeruginosa 123, obtained 
from Prof Monzer Hamza, Laboratoire Microbiolo-
gie Santé et Environnement (LMSE), Ecole Doctorale 
des Sciences et de Technologie, Faculté de Santé 
Publique, Université Libanaise, Tripoli, Lebanon).
Agarose gel preparation for gel 
electrophoresis
Tris Base EDTA (TBE) 1X buffer was prepared; by 
one part of stock solution 10X with nine parts of 
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distilled water. The agarose gel at concentration 
of 2% was prepared by dissolving 3.6 gram of 
agarose powder in 180 ml of 1X buffer and boiling 
in microwave until agarose completely dissolved, 
then 8 μl of ethidium bromide (10 mg/ml) was 
added. The agarose was poured into the electro-
phoresis tray and left to solidify at room tempe-
rature for 20 minutes. After removal of coombs 
and gates, the gel placed in the electrophoresis 
tank pre-filled with 1X TBE buffer to be loaded 
with PCR products.
Statistical analysis
Data were analyzed using Statistical Package for 
Social Sciences (IBM SPSS) version 21. The level of 
significance was set at a P value of ≤0.05 to test 
the hypothesis of no association. 
Results 
A total of 287 fecal samples were obtained from 
adult students. Of these samples, 88 were males 
(30.7%) with average age 21.56 ± 2.26 years and 
199 (69.3%) were females with average age 21.8 ± 
3.32 years (Table 2). The antimicrobial susceptibility 
pattern of 287 E. coli isolates is shown in Table 3. 
Table 2.  Demographic characteristics of 287 adults 
whose fecal samples were cultured for E. 
coli isolates*. 
Characteristics
Male Females Total no
No. % No. % No. %
Age (years) 88 30.7 199 69.3 287 100
Mean ± SD 21.58 ± 2.26 21.80 ± 3.32
Age-range 
(years)
18-34 18-35 
*: The majority of students visited the clinical for treatment of respiratory 
tract infection. About one third of the students have stated that they have 
taken antibiotics during the 6 months before sampling their stools. 
Table 1.  Primer targets, sequences, product sizes and references, positive control strains used in the study.
Target genes Primer sequence Product size(bp) Autor Year
CTX-M group-1 M13U (5’GGTTAAAAAATCACTGCGTC-3’ )
M13L (5’-TTGGTGACGATTTTAGCCGC- 3’ ) 
863 Leflon-Guibout 2004
CTX-M-15 
F-CTX-M-F1 (5’ATAAAACCGGCAGCGGTG-3’)
R-CTX-M-F2 (5’-GAATTTTGACGATCGGGG-3’) 
483 Leflon-Guibout 2004
ParC
F (5’-CGATTGCCGCCTGAGCCACTT-3’)
R (5’-GCGAATAAGTTGAGGAATCAG-3’) 
605 Leflon-Guibout 2004
gyrA 
F (5’-CGACCTTGCGAGAGAAAT-3’)
R (5’-GTTCCATCAGCCCTTCAA-3’) 
625 Leflon-Guibout 2004
KPC 
F (5’-ATGTCACTGTATCGCCGTCT- 3’)
R (5’-TTACTGCCCGTTGACGCCCA-3’) 
880 Pillai 2009 
VIM 
F (5’-GTTTGGTCGCATATCGCAAC-3’)
R (5’-AATGCGCAGCACCAGGATAG-3’) 
382 Pitout 2005 
IMP 
A (5’-GAAGGCGTTTATGTTCATAC-3’) 
B (5’-GTACGTTTCAAGAGTGATGC-3’) 
587 Pitout 2005 
NDM-1 
F (5’-GGTGCATGCCCGGTGAAATC-3’) 
R (5’-ATGCTGGCCTTGGGGAACG-3’) 
660 Bonnin 2012 
OXA-48 
A (5’- TTGGTGGCATCGATTATCGG-3’) 
B (5’-GAGCACTTCTTTTGTGATGGC-3’) 
743 Poirel 2004 
trpA 
F (5’-GCTACGAATCTCTGTTTGCC-3’) 
R (5’-GCAACGCGGCCTGGCGGAAG-3’) 
427 Clermont 2009
pabB 
F (5’-TCCAGCAGGTGCTGGATCGT-3’) 
R (5’-GCGAAATTTTTCGCCGTACTGT-3’) 
347 Clermont 2009
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Minimum inhibitory concentrations (MICs) of Multi-
ple Drug Resistant (MDR) E. coli and the MIC ranges 
for three tested antibiotics (ciprofloxacin, imipenem 
and meropenem) are given in Table 4. The distribu-
tion of genes for ESBLs, quinolone-resistance, and 
ST131 clone among 51 MDR representative E. coli 
isolates are demonstrated in Table 5. 
Sequencing results for ST131 strains
Three randomly picked positive E. coli ST131 isola-
tes were sent for sequencing to Genewiz company, 
USA. The sequencing results were analyzed by using 
the website http://www.ecogene.org/gene. Interroga-
tion of the gene database registered sequences 
with identity homologies were between 98-99% 
for pabB in three isolates.
Discussion
This study investigated antibiotic resistance profiles 
for 287 E. coli isolates from fecal samples of adults 
visiting the students’ clinic of the University of Jor-
dan. The study found that 36.6% (105) of these stu-
dents carried MDR fecal E. coli for at least 3 classes 
of antibiotics. E. coli ESBL-producers were found to 
be 45.1% among 105 MDR tested isolates. These 
results are similar to two recent studies examined 
fecal samples from hospitalized and out-patient in-
fants admitted to the Pediatric Clinic at JUH during 
the years 2011 to 2014, and both studies reported 
rates of 30.6% and 42% MDR E. coli isolates which 
were ESBL-producers [4, 6]. 
The emergence of antimicrobial resistance is be-
coming a serious global health problem worldwide, 
especially among pathogenic E. coli [1, 23]. Most 
Table 3.  Antimicrobial susceptibility patterns of 287 
E. coli isolates*.
Antimicrobial drug
resistant isolates
No. % 
Ampicillin  141 49.1
Cefuroxime 139 48.4
Nalidixic acid 126 44
Tetracycline 124 43.2 
Co-trimoxazole 97 33.1
Cefotaxime 46 16
Ciprofloxacin 41 14.3 
Gentamicin 24 8.4 
Ceftazidime 22 7.6 
Imipenem 17 5.9 
Amikacin 03 1
*: 105 of E. coli isolates (36.6%) were considered as MDR(resistant for at least 3 
antibiotic classes) and 45.1% were ESBL-producers.
Table 5.  Distribution of ESBLs genes, quinolone-
resistance, and ST131 among 51 represen-
tative MDR E. coli isolates*.
Specific genes
Positive E. coli isolates
No. % 
blaCTXM group-I 30 58.8 
blaCTXM-15 21 41.2 
blaKPC 6 11.8 
blaNDM-1 6 11.8 
blaVIM 1 2.0 
blaIMP Null 
blaOXA-48 Null 
ParC 51 100 
gyrA 51 100 
ST131 25 49
*: Resistant isolates to at least antibiotic classes (ampicillin, cotrimoxazole, 
cefuroxime).
Table 4.  Minimum inhibitory concentration range 
with MIC50 and MIC90 for three tested 
antibiotics*.
Antimicrobial 
drug
MIC50 MIC90 
MIC 
Range 
Breakpoints 
for 
susceptible
μg/mL μg/mL μg/mL μg/mL
Ciprofloxacin 9.9 17.8 0.002-32 ≤ 0.06 
Imipenem 0.1 0.17 0.002-32 ≤ 1 
Meropenem 0.03 0.05 0.002-32  ≤ 1
*: According to CLSI 2015 guidelines.
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published data on antimicrobial resistance were ob-
tained from hospitalized or out-patients. Few stu-
dies have investigated the occurrence of antimicro-
bial resistance in a community population. Healthy 
individuals may carry MDR fecal E. coli, and these 
individuals can spread their resistant E. coli in their 
community, and might be a potential source of 
community infections [24]. 
A recent study, which was carried at the same 
period in four medical centers in Jordan and Le-
banon over the period between 2011 and 2013, 
and included samples from patients have UTI and 
intra-abdominal infection (IAI), has shown that 
ESBL-producers among E. coli isolates were 43% 
and 49% in UTI and IAI samples, respectively 
[26]. A Libyan study investigated 333 Enterobac-
teriaceae isolates from both patients and healthy 
controls, and found only 15 (4.5%) isolates were 
positive for ESBL using the double disc synergy 
test. The Libyan study also detected that patients 
were infected with 5.4% of E. coli and 11.4% of 
K. pneumoniae isolates which were ESBL-produ-
cers. Additionally, the study indicated that almost 
all the ESBL-producing isolates were consistently 
more resistant to a wide variety of antimicrobial 
agents than the non-ESBL-producers as it is the 
case in our study [27]. The low incidence of ESBL-
producers in the Libyan study may be due to use 
a detection test which is not sensitive enough like 
molecular detection using PCR which was applied 
in our study and often in other studies. Other 
recent studies from the Arab Middle East region 
documented that rates of E. coli ESBL-producers 
remain higher in clinical samples when compared 
to healthy persons [5, 28]. 
This study showed a relatively high percentage 
of blaCTX-M group I and blaCTX-M-15 among the 
MDR E. coli isolates (58.8% and 41.2%, respecti-
vely). It has been previously documented that blaC-
TX-M-15 group is widely prevalent in Arab Middle 
East region [3-7]. Currently, blaCTX-M-15 type is 
commonly detected in ESBL positive Enterobacteria-
ceae and others Gram-negative pathogens through 
the whole world [2, 29]. 
This study also demonstrated presence of diffe-
rent β-lactamases other than CTX-M types such as 
KPC, NDM-1 which had been detected in 11.8%, 
and VIM in 2% of MDR isolates, while no detection 
of IMP and OXA-48 was recognized (Table 5). These 
results are novel, since no previous study in Jordan 
has reported on the occurrence of KPC, NDM-1 
β-lactamases in E. coli isolates from any source. 
This study detected ParC and gyrA quinolone-
resistance genes among all 51 MDR E. coli isolates. 
This high percentage may indicate extensive con-
sumption of fluoroquinolones in Jordan according 
to our available information. Another suspected 
factor which may contribute to high fluoquinolo-
ne-resistance is the dissemination of ST131 E. coli 
clone [4, 30]. The present study shows that E. coli 
ST131 clone carrying the pabB gene and cipro-
floxacin-resistant was accounted for 49% of MDR 
E. coli isolates. This result is relatively high when 
compared to a recent study investigated fecal E. 
coli isolates from Jordanian infants admitted to the 
JUH, and found only 9 isolates (7.2%) to be posi-
tive for ST131 clone [4]. A study in US found that 
ST131 accounted for 46% of ESBL-positive E. coli 
isolates [30]. Other studies from developed coun-
tries reported on the emergence of E. coli ST131 
types in geriatric patients and among hospitalized 
patients colonized intestinally with fluoroquinolo-
ne-resistant E. coli. [30-32]. In addition, a recent 
paper from Japan, found Type 131 C1-M27 sub-
clone, among ESBL-Producing E. coli in wastewater 
[33].
This study suggests that continuous increasing in-
cidence of E. coli producing ESBL and fluoquinolone-
resistance in intestinal tract of population would make 
the treatment of infections caused by E. coli, especially 
community UTIs more difficult and challenging.
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